These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33668085)

  • 1. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.
    Chourasia M; Koppula PR; Battu A; Ouseph MM; Singh AK
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33668085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
    Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
    Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of EGCG oxidation on inhibitory activity against the SARS-CoV-2 main protease.
    He Y; Hao M; Yang M; Guo H; Rayman MP; Zhang X; Zhang J
    Int J Biol Macromol; 2024 Aug; 274(Pt 2):133451. PubMed ID: 38944088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection.
    Bimonte S; Forte CA; Cuomo M; Esposito G; Cascella M; Cuomo A
    Drug Des Devel Ther; 2021; 15():4447-4454. PubMed ID: 34737551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the Trans-Epithelial Transport of Green Tea (
    Montone CM; Aita SE; Arnoldi A; Capriotti AL; Cavaliere C; Cerrato A; Lammi C; Piovesana S; Ranaldi G; Laganà A
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
    Henss L; Auste A; Schürmann C; Schmidt C; von Rhein C; Mühlebach MD; Schnierle BS
    J Gen Virol; 2021 Apr; 102(4):. PubMed ID: 33830908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study.
    Tan Q; Duan L; Ma Y; Wu F; Huang Q; Mao K; Xiao W; Xia H; Zhang S; Zhou E; Ma P; Song S; Li Y; Zhao Z; Sun Y; Li Z; Geng W; Yin Z; Jin Y
    Bioorg Chem; 2020 Nov; 104():104257. PubMed ID: 32927129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19.
    Wang YQ; Li QS; Zheng XQ; Lu JL; Liang YR
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34209485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
    Mirza MU; Ahmad S; Abdullah I; Froeyen M
    Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
    Kiba Y; Tanikawa T; Kitamura M
    Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
    Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
    J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
    Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
    Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2.
    Mhatre S; Naik S; Patravale V
    Comput Biol Med; 2021 Feb; 129():104137. PubMed ID: 33302163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro.
    Kiba Y; Tanikawa T; Hayashi T; Yokogawa T; Sano A; Suzuki R; Kitamura M
    J Nat Med; 2024 Jun; 78(3):784-791. PubMed ID: 38512650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.